Skip to main content

Research Repository

Advanced Search

A sample-to-answer COVID-19 diagnostic device based on immiscible filtration and CRISPR-Cas12a-assisted detection

Ngamsom, Bongkot; Iles, Alexander; Kamita, Moses; Kimani, Racheal; Wakaba, Patrick; Rodriguez-Mateos, Pablo; Mungai, Mary; Dyer, Charlotte E.; Walter, Cheryl; Gitaka, Jesse; Pamme, Nicole

Authors

Bongkot Ngamsom

Alexander Iles

Moses Kamita

Racheal Kimani

Patrick Wakaba

Pablo Rodriguez-Mateos

Mary Mungai

Jesse Gitaka

Nicole Pamme



Abstract

In response to the ongoing coronavirus disease 2019 (COVID-19) pandemic and disparities of vaccination coverage in low-and middle-income countries, it is vital to adopt a widespread testing and screening programme, combined with contact tracing, to monitor and effectively control the infection dispersion in areas where medical resources are limited. This work presents a lab-on-a-chip device, namely ‘IFAST-LAMP-CRISPR’, as an affordable, rapid and high-precision molecular diagnostic means for detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The herein proposed ‘sample-to-answer’ platform integrates RNA extraction, amplification and molecular detection with lateral flow readout in one device. The microscale dimensions of the device containing immiscible liquids, coupled with the use of silica paramagnetic beads and guanidine hydrochloride, streamline sample preparation (including RNA extraction, concentration and purification) in 15 min with minimal hands-on steps. The pre-amplification in combination with CRISPR-Cas12a detection assays targeting the nucleoprotein (N) gene achieved visual identification of ≥ 470 copies mL−1 genomic SARS-CoV-2 samples in 45 min. On-chip assays showed the ability to isolate and detect SARS-CoV-2 RNA from 100 genome copies mL−1 of replication-deficient viral particles in 1 h. This simple, affordable and integrated platform demonstrated a visual, faster, and yet specificity- and sensitivity-comparable alternative to the costly gold-standard reverse transcription-polymerase chain reaction (RT-PCR) assay, requiring only a simple heating source. Initial testing illustrates the platform viability both on nasopharyngeal swab and saliva samples collected using the easily accessible Swan-brand cigarette filter, providing a complete workflow for COVID-19 diagnostics in low-resource settings.

Citation

Ngamsom, B., Iles, A., Kamita, M., Kimani, R., Wakaba, P., Rodriguez-Mateos, P., Mungai, M., Dyer, C. E., Walter, C., Gitaka, J., & Pamme, N. (2022). A sample-to-answer COVID-19 diagnostic device based on immiscible filtration and CRISPR-Cas12a-assisted detection. Talanta Open, 6, Article 100166. https://doi.org/10.1016/j.talo.2022.100166

Journal Article Type Article
Acceptance Date Nov 2, 2022
Online Publication Date Nov 8, 2022
Publication Date Dec 1, 2022
Deposit Date Aug 9, 2024
Publicly Available Date Aug 9, 2024
Journal Talanta Open
Electronic ISSN 2666-8319
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 6
Article Number 100166
DOI https://doi.org/10.1016/j.talo.2022.100166
Keywords COVID-19; Immiscible filtration; CRISPR-Cas; Diagnostics; Point-of-care; SARS-CoV-2
Public URL https://hull-repository.worktribe.com/output/4786168
This output contributes to the following UN Sustainable Development Goals:

SDG 3 - Good Health and Well-Being

Ensure healthy lives and promote well-being for all at all ages

Files




You might also like



Downloadable Citations